Summit Therapeutics says cash crunch could impact its ability to continue
Seeking Alpha ·
Summit Therapeutics ( SMMT ) indicated after Thursday's closing bell that its current cash, cash equivalents, and short-term investments are not enough to fund its operation for at least the next year. Shares are down ~5% in after-hours trading.
DYAX Investor Sentiment
Bullish (Long) 65% · Bearish (Short) 35%
330 participants
Related News
- EnerSys awarded revised $150M DoE grant for lithium cell manufacturing plant
- Community Health Systems forecasts 2026 adjusted EBITDA of $1.3B-$1.375B amid softer elective surgeries and higher uninsured volumes
- AI Chip Stocks Just Got Crushed. 3 Semiconductor ETFs to Buy the Dip On
- Rivian Automotive (RIVN) As June Quarter Results Near Fair Value Stays In Focus
- VeriSign Q2 Earnings Call Highlights
- Galway Metals begins drilling at Estrades project under DOWA joint venture
